Skip to main content
OpenTrials

Clinical trial condition

Mantle Cell Lymphoma

Explore clinical trials studying Mantle Cell Lymphoma. Study availability and eligibility vary by location and protocol.

251 public trials 59 recruiting studies
Refine in advanced search Browse all conditions

Mantle Cell Lymphoma trial results

Active, Not Recruiting

Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

NCT04802590

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • A.Z. Sint Jan AV Bruges, Belgium
  • Universite Libre de Bruxelles - Hopital ERASME Brussels, Belgium
  • Hopital Jolimont Haine-Saint-Paul, Belgium
  • CHU de Liege Liège, Belgium
View all 45 locations
View Trial Details
Active, Not Recruiting

Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma

NCT06504199

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Institute of Hematology & Blood Diseases Hospital Tianjin, Tianjin Municipality, China
  • Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences Tianjin, Tianjin Municipality, China
View Trial Details
Active, Not Recruiting

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

NCT05020678

Conditions
Aggressive Lymphoma, B-cell Acute Lymphoblastic Leukemia, Blood Protein Disorders, +43 more
Locations
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • The Cleveland Clinic Foundation Cleveland, Ohio, United States
  • Institute of Haematology, Royal Prince Alfred Hospital Camperdown, New South Wales, Australia
  • St. Vincent's Hospital Sydney, New South Wales, Australia
View Trial Details
Active, Not Recruiting

Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL

NCT02682641

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Hospital Clínic de Barcelona Barcelona, Spain
  • Hospital de la Santa Creu i Sant Pau Barcelona, Spain
  • Hospital Universitario Vall d'Hebron Barcelona, Spain
  • Institut Català d'Oncologia Barcelona, Spain
View all 15 locations
View Trial Details
Active, Not Recruiting

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

NCT06192888

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Dana Farber Cancer Institute (Data Collection and Specimen Analysis) Boston, Massachusetts, United States
  • Mayo Clinic (Data Collection Only) Rochester, Minnesota, United States
  • Washington University (Data Collection Only) St Louis, Missouri, United States
  • Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
View Trial Details

Related conditions